1. Home
  2. BMA vs IMVT Comparison

BMA vs IMVT Comparison

Compare BMA & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Banco Macro S.A.  ADR (representing Ten Class B)

BMA

Banco Macro S.A. ADR (representing Ten Class B)

HOLD

Current Price

$91.26

Market Cap

5.1B

Sector

Finance

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$26.85

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMA
IMVT
Founded
1966
2018
Country
Argentina
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1B
5.3B
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
BMA
IMVT
Price
$91.26
$26.85
Analyst Decision
Strong Buy
Buy
Analyst Count
4
10
Target Price
$96.33
$27.75
AVG Volume (30 Days)
323.4K
1.9M
Earning Date
11-26-2025
02-05-2026
Dividend Yield
2.33%
N/A
EPS Growth
N/A
N/A
EPS
0.26
N/A
Revenue
$1,943,401,172.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.56
N/A
P/E Ratio
$36.44
N/A
Revenue Growth
N/A
N/A
52 Week Low
$38.30
$12.72
52 Week High
$118.42
$27.69

Technical Indicators

Market Signals
Indicator
BMA
IMVT
Relative Strength Index (RSI) 61.04 63.69
Support Level $89.18 $26.35
Resistance Level $93.50 $27.64
Average True Range (ATR) 4.18 1.36
MACD -0.15 0.16
Stochastic Oscillator 75.49 84.89

Price Performance

Historical Comparison
BMA
IMVT

About BMA Banco Macro S.A. ADR (representing Ten Class B)

Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. It generates the majority of its revenue from Argentina.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: